LIVE

PAHC

Phibro Animal Health Corporation

PAHC

NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $1.3B

$33.26

▲ +3.61%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$25.58 - $60.08

P/E

14.78

Fwd P/E

9.95

Beta

0.46

Div Yield

1.50%

Avg Vol

354.8K

Shares Out

40.5M

Mkt Cap

$1.3B

Price action

Price chart

Up 14.9% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

4 reasons

  • Integrated product portfolio addressing multiple animal health and nutrition needs across major livestock species
  • Established distribution network through direct sales offices and partnerships with feed manufacturers and integrators
  • Specialized manufacturing capabilities for trace minerals and specialty chemical formulations with industrial applications
  • Global geographic diversification across six continents reducing market concentration risk
▼

Bear Case

2 risks

  • Low volatility (beta 0.5).
  • Growth premium of 0.7x vs Large Cap Pharma peers. Reasonable for this growth rate.

Growth

Stable outlook

Rising global demand for animal protein and livestock productivity optimization

Value

Growth premium of 0.7x vs Large Cap Pharma peers. Reasonable for this growth rate.

Momentum

Falling

-42.2% over 3m

Quality

Stable

High-growth business (32% revenue growth, 32% gross margin). Profitable with strong growth momentum.

Dividend

Modest

1.50% yield

Earnings track record

Latest print - beat on both lines

AI-summarized recap of last quarter, plus the surprise on every print.

Next: May 5, 2026

“
Q2 26 RECAP

MAY 6, 2026

Reported EPS of $0.76 vs $0.72 consensus (+5.6% surprise). Revenue of $383.5M vs $367.0M expected (+4.5%). Beat on both top and bottom lines.

EPS beat +5.6%
Rev beat +4.5%
Double beat

EPS surprise · last 4Q

1 of 1 beats

Q2 26

+5.6%

Next: May 5, 2026

Revenue trend · last 8Q

—

—

—

+24%

+32%

+39%

+40%

+21%

Q3 24

Q4 24

Q1 24

Q2 24

Q3 25

Q4 25

Q1 25

Q2 25

$263.2M

$273.2M

$260.4M

$309.3M

$347.8M

$378.7M

$363.9M

$373.9M

Margins · last 8Q

Gross

35.5%

Operating

14.6%

Profit

7.3%

View full earnings history →

Wall Street consensus

1 analyst · 0% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

0%

Hold

1

100%

Sell

0%

Median Price Target

—

Latest: Citi · May 14, 2026

View full analyst page →

vs Industry

How PAHC stacks vs Drug Manufacturers - Specialty & Generic

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.